Acta Scientific Medical Sciences (ISSN: 2582-0931)

Review Article Volume 4 Issue 5

Diagnostic Strategies for COVID-19

Krishan Karla1, Shashidhar KN2, Krishna S Nallagangula3*

1Senior Scientist, Founder and CEO, BioGenex Laboratories, Fremont, California, United States of America
2Professor and HOD, Co-ordinator, R&D, Vice Principal, Sri Devaraj Urs Medical College, SDUAHER, Kolar, Karnataka, India
3Molecular Pathology Scientist, BioGenex Life Sciences Pvt Ltd, Adibatla, Hyderabad, Telangana, India

*Corresponding Author: Krishna S Nallagangula, Molecular Pathology Scientist, BioGenex Life Sciences Pvt Ltd, Adibatla, Hyderabad, Telangana, India.

Received: March 30, 2020; Published: April 08, 2020



  COVID-19; single stranded positive RNA (+ssRNA) virus causes common cold to severe diseases viz., Severe Acute Respiratory Syndrome (SARS). At this point of time, prevalence of this pandemic virus increases exponentially and become global health burden. Asymptomatic/paucisymptomatic respiratory failure; characterized by leucopenia, leukocytosis, lymphonia and thrombocytopenia along with elevated levels of hepatic aminotransferases [Aspartate transaminase (AST) and Alanine Transaminase (ALT)] and lactate dehydrogenase (LDH). Detection of viral genome by reverse transcription polymerase chain reaction (RT-PCR) is the World Health Organization (WHO) recommended diagnostic modality. Enhanced inflammatory cytokines level will be observed in serum of severe patients. In the present scenario, therapeutic strategies for this infection are only supportive. Drastic research is needed for structural characterization of virus and pathophysiology of the disease. There is a need for strengthening of research in diagnostic and therapeutic areas to control the prevalence and cure the disease; increases survival rate with decreased mortality. Aggressive social isolation is the best way for progressive reduction of prevalence.

Keywords: Single Stranded Positive RNA (+ssRNA); Aspartate Transaminase (AST); Alanine Transaminase (ALT); Lactate Dehydrogenase (LDH); Reverse Transcription Polymerase Chain Reaction (RT-PCR); World Health Organization (WHO)



  1. Chan JF., et al. “Interspecies transmission and emergence of novel viruses: lessons from bats and birds”. Trends in Microbiology 10 (2013): 544-555.
  2. Cascella M., et al. “Features, evaluation and treatment coronavirus (COVID-19)” (2020).
  3. Chen Y., et al. “Emerging coronavirus: Genome structure, replication and pathogenesis”. Journal of Medical Virology 4 (2020): 418-423.
  4. Malik YS., et al. “Emerging novel coronavirus (2019-n Co V) - current scenario, evolutionary perspective based on genome analysis and recent developments”. Veterinary Quarterly1 (2020): 68-76.
  5. Chan JF., et al. “Genomic characterization of the 2019 novel human pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emerging Microbes and Infections 1 (2020): 221-236.
  6. Sawicki SG., et al. “A contemporary view of coronavirus transcription”. Journal of Virology 1 (2007): 20-29.
  7. Periman S., et al. “Coronaviruses post-SARS: update on replication and pathogenesis”. Nature Reviews Microbiology 6 (2009): 439-450.
  8. Beniac DR., et al. “Architecture of the SARS coronavirus perfusion spike”. Nature Structural and Molecular Biology 8 (2006): 751-752.
  9. Hoffmann M., et al. “SARS-Co V-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell 181 (2020): 1-10.
  10. Nal B. “Differential maturation and sub cellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E”. Journal of General Virology 5 (2005): 1423-1434.
  11. Neuman BW., et al. “A structural analysis of M protein in coronavirus assembly and morphology”. Journal of Structural Biology 1 (2011): 11-22.
  12. Nieto-Torres JL., et al. “Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis”. PLOS Pathogens 5 (2014): e1004077.
  13. Fehr AR., et al. “Coronavirus: an overview of their replication and pathogenesis”. Methods in Molecular Biology 1282 (2015): 1-23.
  14. Hurst KR., et al. “Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein”. Journal of Virology14 (2009): 7221-7234.
  15. Li Q., et al. “Early transmission dynamics in Wuhan, China of novel coronavirus-infected Pnemonia”. The New England Journal of Medicine (2020).
  16. Wu Z., et al. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: Summary of a report of 72314 cases from the Chinese centre for disease control and prevention”. Journal of the American Medical Association (2020).
  17. World Health Organization. Laboratory testing for coronavirus disease 2019 (‎COVID-19)‎ in suspected human cases: interim guidance (2020).
  18. Sah R., et al. “Complete genome sequence of a 2019 novel coronavirus (SARS-Co B-2) strain isolated in Nepal”. Microbiology Resource Announcements 9 (2020): e00169-20.
  19. , et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020).
  20. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet (2020).
  21. Kogan A., et al. “Acute respiratory distress syndrome following cardiac surgery: Comparison of the American – European consensus conference definitions versus the Berlin definition”. Respiration6 (2019): 518-524.
  22. Poon LL., et al. “Identification of a novel coronavirus in bats”. Journal of Viral 79 (2005): 2001-2009.
  23. Tools to support new coronavirus research.


Citation: Krishna S Nallagangula., et al. “Diagnostic Strategies for COVID-19". Acta Scientific Medical Sciences 4.5 (2020): 18-21.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

Contact US